Abstract
CD147 is a membrane protein belonging to immunoglobulin superfamily and expressed in the cell membrane, which is also named with an extracellular matrix metalloproteinase inducer (EMMPRIN) because this molecule induces adjacent fibroblasts or tumor cells to produce MMPs, facilitating tumor cells migration and invasion. Accumulating evidences have shown that CD147 is over-expressed in various tumors, including melanoma, liver cancer, and lung cancer, and orchestrates tumor cell proliferation, apoptosis, invasion and metastasis, multidrug resistance and glycolysis through critical molecules such as MMPs, MCTs, Caveolin-1, and VEGF. In this review, we focus on understanding the characteristics of CD147 in various biological functions, including physiological and pathological processes. Recent novel studies have shown that CD147 is not only a potential diagnostic marker but also a therapeutic target for chemotherapy or the diagnosis of cancer.
Keywords: CD147, MMPs, metastasis and invasion, glycolysis, therapeutic target, melanoma.
Current Pharmaceutical Design
Title:Targeting CD147 is a Novel Strategy for Antitumor Therapy
Volume: 23 Issue: 29
Author(s): ChengXiang Lian*, Yeye Guo*, Jianglin Zhang*, Xiang Chen and Cong Peng
Affiliation:
- Department of Dermatology, Xiangya Hospital, Central South University, Xiangya Road #87, Changsha, Hunan, 410008,China
- Department of Dermatology, Xiangya Hospital, Central South University, Xiangya Road #87, Changsha, Hunan, 410008,China
- Department of Dermatology, Xiangya Hospital, Central South University, Xiangya Road #87, Changsha, Hunan, 410008,China
Keywords: CD147, MMPs, metastasis and invasion, glycolysis, therapeutic target, melanoma.
Abstract: CD147 is a membrane protein belonging to immunoglobulin superfamily and expressed in the cell membrane, which is also named with an extracellular matrix metalloproteinase inducer (EMMPRIN) because this molecule induces adjacent fibroblasts or tumor cells to produce MMPs, facilitating tumor cells migration and invasion. Accumulating evidences have shown that CD147 is over-expressed in various tumors, including melanoma, liver cancer, and lung cancer, and orchestrates tumor cell proliferation, apoptosis, invasion and metastasis, multidrug resistance and glycolysis through critical molecules such as MMPs, MCTs, Caveolin-1, and VEGF. In this review, we focus on understanding the characteristics of CD147 in various biological functions, including physiological and pathological processes. Recent novel studies have shown that CD147 is not only a potential diagnostic marker but also a therapeutic target for chemotherapy or the diagnosis of cancer.
Export Options
About this article
Cite this article as:
Lian ChengXiang*, Guo Yeye*, Zhang Jianglin*, Chen Xiang and Peng Cong, Targeting CD147 is a Novel Strategy for Antitumor Therapy, Current Pharmaceutical Design 2017; 23 (29) . https://dx.doi.org/10.2174/1381612823666170710144759
DOI https://dx.doi.org/10.2174/1381612823666170710144759 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Novel Molecular Anti- Colorectalcancer Conjugate:Chlorambucil-Adipic Acid Dihydrizide-Glutamine
Anti-Cancer Agents in Medicinal Chemistry Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)
Current Cancer Drug Targets Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking
Combinatorial Chemistry & High Throughput Screening Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-Nucleoside HBV Inhibitors
Mini-Reviews in Medicinal Chemistry Percutaneous Laser Ablation of Small Hepatocellular Carcinoma
Current Medical Imaging MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Synthetic Approaches to Functionalized Lipids for Protein Monolayer Crystallizations
Current Organic Chemistry Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Current Drug Safety